Randomized trials in patients with carcinoma of an unknown primary site: The past, the present, and the future

Carcinoma of an Unknown Primary Site

Volumn , Issue , 2006, Pages 105-115

  Fizazi, Karim ^a   Schmoll, Hans Joachim ^b  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 58149297093     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (14)

1. Farrugia DC, Norman AR, Nicolson MC, et al. Unknown primary carcinoma: randomised studies are needed to identify optimal treatments and their benefits. Eur J Cancer 1996; 32A(13):2256-2261.
2. Bugat R, Bataillard A, Lesimple T, et al. FNCLCC. Summary of the standards, options and recommendations for the management of patients with carcinoma of unknown primary site (2002). Br J Cancer 2003; 89(suppl 1):S59-S66. Available at www.fnclcc.fr.
3. Lesimple T, Voigt JJ, Bataillard A, et al. FNCLCC. Clinical practice guidelines: standards, options and recommendations for the diagnosis of carcinomas of unknown primary site. Bull Cancer 2003; 90:1071-1096. Available at www.fnclcc.fr.
4. Woods RL, Fox RM, Tattersall MH, Levi JA, Brodie GN. Metastatic adeno-carcinomas of unknown primary site: a randomized study of two combination-chemotherapy regimens. N Engl J Med 1980; 303:87-89.
5. Milliken ST, Tattersall MH, Woods RL, et al. Metastatic adenocarcinoma of unknown primary site. A randomized study of two combination chemotherapy regimens. Eur J Cancer Clin Oncol 1987;23:1645-1648.
6. Eagan RT, Therneau TM, Rubin J, Long HJ, Schutt AJ. Lack of value for cisplatin added to mitomycin-doxorubicin combination chemotherapy for carcinoma of unknown primary site. A randomized trial. Am J Clin Oncol 1987; 10:82-85.
7. Falkson CI, Cohen GL, Mitomycin C. epirubicin and cisplatin versus mitomy-cin C alone as therapy for carcinoma of unknown primary origin. Oncology 1998; 55:116-121.
8. Dowell JE, Garrett AM, Shyr Y, Johnson DH, Hande KR. A randomized phase II trial in patients with carcinoma of an unknown primary site. Cancer 2001; 91:592-597.
9. Culine S, Lortholary A, Voigt JJ, et al. A Trial of the French Study Group on Carcinomas of Unknown Primary (GEFCAPI 01). Cisplatin in combination with either gemcitabine or irinotecan in carcinomas of unknown primary site: results of a randomized phase II study-trial for the French Study Group on Carcinomas of Unknown Primary (GEFCAPI 01). J Clin Oncol 2003; 21:3479-3482.
10. Assersohn L, Norman AR, Cunningham D, et al. A randomised study of protracted venous infusion of 5-fluorouracil (5-FU) with or without bolus mitomy-cin C (MMC) in patients with carcinoma of unknown primary. Eur J Cancer 2003; 39:1121-1128.
11. Huebner G, Steinbach S, Kohne CH, Stahl M, Kretzschmar A, Eimermacher A. Link H on behalf of the German CUP Study Group. Paclitaxel (P)/ carboplatin (C) versus gemcitabine (G)/ vinorelbine (V) in patients with adeno- or undiffer-entiated carcinoma of unknown primary (CUP)-a randomized prospective phase-II-trial. Proc Am Soc Clin Oncol 2005; 23:330s (Abstr 4089).
12. Culine S, Kramar A, Saghatchian M, et al. French Study Group on Carcinomas of Unknown Primary. Development and validation of a prognostic model to predict the length of survival in patients with carcinomas of an unknown primary site. J Clin Oncol 2002; 20:4679-4683.
13. Hainsworth JD, Lennington WJ, Greco FA. Overexpression of Her-2 in patients with poorly differentiated carcinoma or poorly differentiated adeno-carcinoma of unknown primary site. J Clin Oncol 2000; 18:632-635.
14. Fizazi K, Voigt JJ, Lesimple T, et al. Carcinoma of unknown primary (CUP): are tyrosine kinase receptors HER-2, EGF-R, and c-KIT suitable targets for therapy? Proc Am Soc Clin Oncol 2003; 22:883.